Same here. I only bought a few shares, but got them at $17 (when they were CCIV) and they are now ~ $50 less than a year later. I don't profess to know too much about the company but there's plenty of people who think there's more room to grow here.I also have some shares in another fairly new EV company Lucid (LCID). Bought in cheap when it was rumored to be merging with a Saudi investment fund as a SPAC. They have recently started to produce their first cars and the rollout process has begun after selling a few thousand of their new car. Compared with Rivian (who are yet to produce one car), I think Lucid are much better value and will have a good run-up in the years to come.
Yep that was it CCIV. I bought 100 shares at $12, got on it really early.Same here. I only bought a few shares, but got them at $17 (when they were CCIV) and they are now ~ $50 less than a year later. I don't profess to know too much about the company but there's plenty of people who think there's more room to grow here.
The gains here are helping me offset my losses, including NIO, which I hope will rise again soon.
Recovering a bit now, port folio is about 5% down in total after an initial 7%.Carnage this morning.
I suspect gold will do well.
What has prompted it?Carnage this morning.
I suspect gold will do well.
New South African mutated Covid variantWhat has prompted it?
Better news today with travel stocks leading the way. I think there's a feeling that Omicron isn't going to be as bad as the doom mongers have suggested.Unsurprisingly it’s travel related stocks that have taken the brunt of this.
Been a very lacklustre share over the last 5 years this one. Good dividend thoughGSK might be worth a punt. UK regulator approved this drug today. Shares haven't reacted yet.
Early data suggest GSK antibody treatment is effective against Omicron
GlaxoSmithKline’s Covid-19 antibody treatment is likely to be able to tackle the Omicron coronavirus variant, according to early data from the company, despite rival drugs losing efficacy against the recently discovered strain.
The UK drugmaker and its partner Vir Biotechnology said on Thursday that early tests suggest the antibody treatment, called sotrovimab, is effective against Omicron’s key mutations. But the companies’ paper has not yet been peer-reviewed and they still need to complete lab tests of sotrovimab. The companies will provide an update by the end of 2021.
By contrast, early tests of Regeneron’s antibody treatment Ronapreve found the mutations in Omicron may hamper the drug’s ability to treat Covid-19.
Hal Barron, GSK’s chief scientific officer, said the company was working to expand access to the treatment worldwide.
“Though early, these pre-clinical data support our long-held view on the potential for sotrovimab to maintain its activity as the virus continues to mutate,” he said.
Separately on Thursday, the UK regulator approved the drug for high risk people with mild and moderate disease. The Medicines and Healthcare Products Regulatory Agency said it would work with GSK to establish if Omicron will have any impact on its efficacy.
Dr June Raine, MHRA chief executive said: “This is yet another therapeutic that has been shown to be effective at protecting those most vulnerable to Covid-19, and signals another significant step forward in our fight against this devastating disease.”
Think that might change with the U.S activists Elliott group taking a big chunk in the company earlier this year as they have a good track record of investing in undervalued stock and realizing shareholder value and seem to be going for the chairman Walmsley. Glaxo are also splittping the pharma and consumer businesses into two companies next year to refocus on getting a good pipeline of therapeutics to market which they were once renowned for and have just poached Pfizer’s top vaccine man. Doing very promising stuff on hiv as well…Been a very lacklustre share over the last 5 years this one. Good dividend though
I topped up on GSK for just over £12 in Feb. Should have bought more!Been a very lacklustre share over the last 5 years this one. Good dividend though
Wealthsimple is closing down.Was there a big drop today?
I put £2500 in a low risk wealthsimple account a month ago and have lost over £100 (lot of that today).
It would be bad to panic and take it all out now, right?
Yes it’s a bit painful. Taken quite a hit on my American and Chinese funds. In it for the longer term though2022 hasn’t exactly started great.
My tech funds make me want to cry right about now.
Crypto tanking as well.
Add me to the list of people who are getting twatted all over the park at the moment! Highlights include the Baillie Gifford American fund which has served me so well in the past 18 months tanking day after day. All my other Baillie Giffords performing badly too. Plus NIO doesn't look like it's going to the moon anytime soon. I was hoping that would be my golden ticket to an early retirement. At this rate, I'll be retiring when I'm about 86 - assuming I'm still around then!Yes it’s a bit painful. Taken quite a hit on my American and Chinese funds. In it for the longer term though
Add me to the list of people who are getting twatted all over the park at the moment! Highlights include the Baillie Gifford American fund which has served me so well in the past 18 months tanking day after day. All my other Baillie Giffords performing badly too. Plus NIO doesn't look like it's going to the moon anytime soon. I was hoping that would be my golden ticket to an early retirement. At this rate, I'll be retiring when I'm about 86 - assuming I'm still around then!
A lot of my profits from it have been wiped out! But yeah, still on the right side by quite a bitHa, you can’t be complaining too much about the BG American if you’ve held it for 18 months!
Scottish Mortgage Trust is doing me the most damage.